These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 10352163

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY, BENCHMRK Study Teams.
    N Engl J Med; 2008 Jul 24; 359(4):355-65. PubMed ID: 18650513
    [Abstract] [Full Text] [Related]

  • 25. The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control.
    Zaunders J, Dyer WB, Churchill M.
    Curr Opin HIV AIDS; 2011 May 24; 6(3):151-6. PubMed ID: 21378562
    [Abstract] [Full Text] [Related]

  • 26. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM, Araneta MR, Deville JG, Spector SA.
    Clin Infect Dis; 2004 Sep 01; 39(5):725-31. PubMed ID: 15356789
    [Abstract] [Full Text] [Related]

  • 27. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, Kuritzkes DR, Fallon MA, Rubin M.
    N Engl J Med; 1995 Dec 21; 333(25):1662-9. PubMed ID: 7477218
    [Abstract] [Full Text] [Related]

  • 28. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, Saurat JH, Clumeck N, Lazzarin A, Mathiesen L.
    N Engl J Med; 1995 Aug 17; 333(7):408-13. PubMed ID: 7616989
    [Abstract] [Full Text] [Related]

  • 29. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J.
    N Engl J Med; 1993 Jul 29; 329(5):297-303. PubMed ID: 8100611
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec 29; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 32. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F, Padilla S, Masiá M, Iribarren JA, Moreno S, Viciana P, Muñoz L, Gómez Sirvent JL, Vidal F, López-Aldeguer J, Blanco JR, Leal M, Rodríguez-Arenas MA, Perez Hoyos S, CoRIS-MD.
    PLoS One; 2006 Dec 20; 1(1):e89. PubMed ID: 17183720
    [Abstract] [Full Text] [Related]

  • 33. An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC).
    Birch MR, Learmont JC, Dyer WB, Deacon NJ, Zaunders JJ, Saksena N, Cunningham AL, Mills J, Sullivan JS.
    J Clin Virol; 2001 Oct 20; 22(3):263-70. PubMed ID: 11564591
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of long-term infection with nef-defective attenuated HIV type 1 on CD4+ and CD8+ T lymphocytes: increased CD45RO+CD4+ T lymphocytes and limited activation of CD8+ T lymphocytes.
    Zaunders JJ, Geczy AF, Dyer WB, McIntyre LB, Cooley MA, Ashton LJ, Raynes-Greenow CH, Learmont J, Cooper DA, Sullivan JS.
    AIDS Res Hum Retroviruses; 1999 Nov 20; 15(17):1519-27. PubMed ID: 10580402
    [Abstract] [Full Text] [Related]

  • 36. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.
    Verity EE, Zotos D, Wilson K, Chatfield C, Lawson VA, Dwyer DE, Cunningham A, Learmont J, Dyer W, Sullivan J, Churchill M, Wesselingh SL, Gabuzda D, Gorry PR, McPhee DA.
    J Virol; 2007 Sep 20; 81(17):9268-78. PubMed ID: 17567690
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Identification of a new recipient in the Sydney Blood Bank Cohort: a long-term HIV type 1-infected seroindeterminate individual.
    Rhodes D, Solomon A, Bolton W, Wood J, Sullivan J, Learmont J, Deacon N.
    AIDS Res Hum Retroviruses; 1999 Nov 01; 15(16):1433-9. PubMed ID: 10555106
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.